TG Therapeutics, Inc. (TGTX)
NASDAQ: TGTX · Real-Time Price · USD
35.02
-0.48 (-1.35%)
At close: Aug 1, 2025, 4:00 PM
35.29
+0.27 (0.77%)
After-hours: Aug 1, 2025, 7:59 PM EDT
TG Therapeutics Stock Forecast
Stock Price Forecast
The 5 analysts that cover TG Therapeutics stock have a consensus rating of "Strong Buy" and an average price target of $40.8, which forecasts a 16.50% increase in the stock price over the next year. The lowest target is $22 and the highest is $55.
Price Target: $40.80 (+16.50%)
Analyst Consensus: Strong Buy
* Price targets were last updated on Mar 4, 2025.
Analyst Ratings
The average analyst rating for TG Therapeutics stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Feb '25 | Mar '25 | Apr '25 | May '25 | Jun '25 | Jul '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 4 | 4 | 4 | 4 | 4 | 3 |
| Buy | 1 | 1 | 1 | 1 | 1 | 1 |
| Hold | 1 | 1 | 1 | 1 | 1 | 1 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 6 | 6 | 6 | 6 | 6 | 5 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $55 | Strong Buy | Reiterates | $55 | +57.05% | Mar 4, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $55 | Strong Buy | Reiterates | $55 | +57.05% | Jan 15, 2025 |
| JP Morgan | JP Morgan | Buy Maintains $30 → $43 | Buy | Maintains | $30 → $43 | +22.79% | Nov 25, 2024 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Maintains $49 → $55 | Strong Buy | Maintains | $49 → $55 | +57.05% | Nov 5, 2024 |
| Goldman Sachs | Goldman Sachs | Hold Maintains $20 → $22 | Hold | Maintains | $20 → $22 | -37.18% | Nov 5, 2024 |
Financial Forecast
Revenue This Year
605.38M
from 329.00M
Increased by 84.00%
Revenue Next Year
843.03M
from 605.38M
Increased by 39.26%
EPS This Year
0.79
from 0.15
Increased by 429.26%
EPS Next Year
1.76
from 0.79
Increased by 121.63%
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 673.9M | 943.7M | 1.2B | ||
| Avg | 605.4M | 843.0M | 1.0B | ||
| Low | 562.6M | 679.1M | 867.3M |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 104.8% | 55.9% | 43.1% | ||
| Avg | 84.0% | 39.3% | 24.0% | ||
| Low | 71.0% | 12.2% | 2.9% |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 1.20 | 2.65 | 3.05 | ||
| Avg | 0.79 | 1.76 | 2.38 | ||
| Low | 0.57 | 1.02 | 1.67 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 698.0% | 233.3% | 73.1% | ||
| Avg | 429.3% | 121.6% | 35.4% | ||
| Low | 278.9% | 28.4% | -5.3% |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.